CAPTRUST Financial Advisors
TLIS

CAPTRUST Financial Advisors’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-55
Closed -$3K – 5188
2021
Q4 		$3K Buy
+55
New +$4.12K ﹤0.01% 4322

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

CAPTRUST Financial Advisors's TLIS Position: Q1 2022 in Review

CAPTRUST Financial Advisors sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q1 2022, closing a stake of 55 shares — an estimated $3K sold.

CAPTRUST Financial Advisors first reported a position in TLIS in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 44 funds tracked by Wall St. Rank hold TLIS as of Q1 2022.

  • CAPTRUST Financial Advisors reported no remaining Talis Biomedical Corporation Common Stock position as of Q1 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 55 Talis Biomedical Corporation Common Stock shares in Q1 2022, an estimated $3K.
  • CAPTRUST Financial Advisors first reported a position in Talis Biomedical Corporation Common Stock in Q4 2021 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Talis Biomedical Corporation Common Stock position peaked at $3K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2022, filed 16 May 2022.